Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term open-label phase 3b study of WS016 for hyperkalemia
CTR20262860Phase 3Active
- Sponsor
- Waterstone Pharmaceuticals
- Start
- Jul 2026
- Modality
- Small Molecules, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems, Non-biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of WS016 in hyperkalemia, sponsored by Waterstone Pharmaceuticals. Primary endpoint: Proportion of participants with mean serum potassium less than or equal to 5.0 mmol/L during the maintenance treatment period. Started Jul 2026; status: active.
02
Drugs
WS016
03
Conditions
hyperkalemia
Beyond the preview
Go deeper on CTR20262860.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20262860.